SINTYA: 10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session
Study summary
Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).
Eligibility
Sex
ALL
Min age
16 Years
Max age
25 Years
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale.
* High BPD severity level: ZAN-BPD (score ≥ 18/36).
* Understand, write and read French.
* Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations.
* Have signed the informed consent.
* For minor patients, have signed the parental consent by at least one holder of parental authority.
Exclusion Criteria:
* Refusal to participate.
* Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance.
* Intelligence quotient \< 70.
* Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7).
* Previous or current participation in specific psychotherapy for BPD.
* Subject deprived of liberty (by judicial or administrative decision) and/or protected by law.
* Inclusion in another study including psychotherapy for the duration of the study.
* Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study.
* Subject in period of exclusion from another research protocol.
Primary outcome measure(s)
Variation in explicit impulsivity between groups — Baseline UPPS-S (Impulsive Behavior Scale Short version score)
Variation in explicit impulsivity between groups — Month 4 UPPS-S (Impulsive Behavior Scale Short version score)
Trial sites (1)
Facility
City
Region
Status
CHU de Nîmes
Nîmes
France
Recruiting
More Centre Hospitalier Universitaire de Nīmes trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
